Рекормон: 20 лет успешного применения в клинике


В.М. Ермоленко, Н.Н. Филатова

ГБОУ ДПО РМАПО Минздравсоцразвития России, Москва
В обзоре на основании анализа мультицентровых контролируемых клинических исследований обсуждаются фармакокинетические особенности, способы введения и преимущества применения эпоэтинов-β больными с уремией; специально названы ситуации, в которых назначение высоких доз рекомбинантного человеческого эритропоэтина опасно с точки зрения развития серьезных осложнений.

Литература


1. Fishbane S., Nissenson A.R. Anemia management in chronic kidney disease. Kidney Int. 2010; 78: S3–S9.
2. D©Andrea A., Lodish H., Wong G. Expression cloning of the murine erythropoietin receptor. Cell. 1989; 57: 277–285.
3. Brockmöller J., Köchling J., Weber W. et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol. 1992; 34: 499–508.
4. Schouten J.P., Voorhorst G., Helbing A.R. Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment. Pharm World Sci. 1993; 15: 252–256.
5. Yang S., Liu P., Wang E., Duan H. Pharmacokinetic studies of recombinant human erythropoietin in fifteen chinese uremic patients. Clin Pharmacol. 1995; 30: 670–672.
6. Weiss L.G., Clyne N., Divino F.G. et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin–beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant. 2000; 15: 2014–2019.
7. Locatelli F., Baldamus C.A., Villa G. et al. Once-weekly compared with threetimes-weekly subcutaneous epoetin β: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002; 40: 119–125.
8. Mathieu C.M., Teta D., Lötscher N. et al. Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland. BMC Nephrol. 2008; 9: 16–27.
9. Lui S.F., Law C.B., Ting S.M. et al. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1991; 36: 246–251.
10. Saleh A., Krane N.K., Caballero M. et al. Once weekly subcutaneous erythropoietin is an effective therapy in the treatment of anemia of end stage renal disease patients on CAPD. Adv Perit Dial 1991; 7: 288–291.
11. Nomato Y., Kawaguchi Y., Kubota M. et al. A multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int. 1994; 14: 56–60.
12. Frifelt J.J., Tvedegaard E., Bruun K. et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int. 1996; 16: 594–598.
13. Grzeszczak W., Sulowicz W., Rutkowski B. et al. The efficacy and safety of once-weekly and once–fortnightly subcutaneous epoetin beta is effective in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant. 2005; 20: 936–944.
14. Koch K.M., Koene R.A., Messinger D. et al. The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol. 1995; 44: 201–208.
15. Albetazzi A., Di Liberato L., Daniele F. et al. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients:results of a multicenter study. Int J Artif Organs. 1998; 21: 12–18.
16. Frenken L.A., van Lier H.J., Gerlag P.G. et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ. 1991; 303: 288–292.
17. Veys N., Dhondt A., Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol. 1998; 49: 41–44.
18. Roger S.D., Suranyi M.G., Walker R.G. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. Curr Med Res Opin. 2008; 24: 2181–2187.
19. Gumming M.N., Sharkey I.M., Sharp J. et al. Subcutaneous erythropoietin alpha (Eprex) is more painful than erythropoietin beta (Recormon). Nephrol Dial Transplant. 1998; 13(3):817.
20. Shigematsu T., Takami H., Shimizu T. et al. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a Multicenter, Open-label Clinical Study. Ther Apher Dial. 2008; 12: 469–474.
21. Томилина Н.А., Бирюкова Л.С., Ушакова А.И. и др. Оценка безопасности и лечебной эффективности нового отечественного средства, стимулирующего эритропоэз, эпоэтина бета по поддержанию
стабильных значений целевого гемоглобина у больных, находящихся на программном гемодиализе. Нефрология и диализ. 2011; 13(2): 25–29.
22. Фролова А.Б., Жмуров В.А. Коррекция анемического синдрома рекомбинантным человеческим эритропоэтином (РЧЭРП “РЕКОРМОН”). Научный вестник Тюменской медицинской академии.
2002; 4: 85–86.
23. Loughnan A., Ali G.R., Abeygunasekara S.C. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients. Ren Fail. 2011; 33: 373–375.
24. Rath T., Mactier R.A., Weinreich T. et al. Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study. Curr Med Res Opin. 2009; 25: 961–970.
25. Deray G. Achieving therapeutic targets in renal anaemia: considering costefficacy. Curr Med Res Opin. 2004; 20: 1095–1101.
26. Ермоленко В.М., Ряженов В.В. О стоимости терапии нефрогенной анемии эпоэтинами. Клиническая фармакология и терапия. 2010; 19 (2): 12–14.
27. Regidor D.L., Kopple J.D., Kovesdy C.P. et al. Associations between Changes in Hemoglobin and Administered Erythropoiesis–Stimulating Agent and Survival in Hemodialysis Patients. J Am Soc Nephrol. 2006; 17: 1181–1191.
28. Collins A.J. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl. 2002; 80: 44–48.
29. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584–590.
30. Drüeke T.B., Locatelli F., Clyne N. et al. for the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–84.
31. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098.
32. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019–2032.
33. Najjar S.S., Rao S.V., Harrington R.A. Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction-Reply. JAMA 2011; 306: 706.
34. Bohlius J., Schmidlin K., Brillant C. et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009; 3: CD007303.
35. Corwin H.L. Erythropoietin use in critically ill patients: forest and trees. CMAJ. 2007; 177: 747–749.
36. Corwin H.L., Gettinger A., Fabian T.C. et al. EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007; 357: 965–976.
37. Stowell C.P., Jones S.C., Enny C. et al. An open-label, randomized, parallelgroup study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976). 2009; 34: 2479–485.
38. Jacques B., Jensen T.S., Rollins J. et al. Proposed decision memo for erythropoiesis stimulating agents (ESAs) for treatment of anemia in adults with CKD including patients on dialysis and patients not on
dialysis (CAG–00413N). Centers for Medicare and Medicaid Services. 2 011; 7.
39. Zhang Y., Thamer M., Kaufman J.S. et al. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int. 2011; 80: 663–669.
40. Betjes M.G., Weimar W., Litjens N.H. CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD. J Am Soc Nephrol. 2009; 20: 2661–2666.
41. Falasca K., Ucciferri C., Mancino P. et al. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. J Med Virol. 2010; 82: 49–56.
42. Abe M., Okada K., Soma M. et al. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. Clin Nephrol. 2011; 75: 49–58.
43. Yuen C.M., Leu S., Lee F.Y. et al. Erythropoietin markedly attenuates brain infarct size and improves neurological function in the rat. J Investig Med. 2010; 58: 893–904.
44. Schiffer M., Park J.K., Tossidou I. et al. Erythropoietin prevents diabetesinduced podocyte damage. Kidney Blood Press Res. 2008; 31: 411–415.


Об авторах / Для корреспонденции


Ермоленко В.М. – профессор, заведующий кафедрой нефрологии и гемодиализа ГБОУ ДПО РМАПО Минздравсоцразвития России, д.м.н. Тел. 8(495) 653-16-42;
Филатова Н.Н. – ГБОУ ДПО РМАПО Минздравсоцразвития России


Похожие статьи


Бионика Медиа